Stay updated on Cabozantinib in Pancreatic Neuroendocrine & Carcinoid Tumors Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib in Pancreatic Neuroendocrine & Carcinoid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib in Pancreatic Neuroendocrine & Carcinoid Tumors Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The condition name was changed from 'Neuroendocrine pancreatic tumor' to 'Neuroendocrine tumor of pancreas' in the study's conditions section.
    Difference
    0.1%
    Check dated 2026-03-27T13:28:44.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    Carcinoid tumor keyword added and page revision updated from v3.4.3 to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-20T07:18:26.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Revision: v3.4.3 is displayed and Revision: v3.4.2 has been removed.
    Difference
    0.1%
    Check dated 2026-03-05T19:41:19.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    The only changes are revision labels added/removed at the bottom of the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-12T02:14:57.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    Revision changed from v3.4.0 to v3.4.1 in the page metadata, with no changes to the study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-04T23:09:42.000Z thumbnail image
  8. Check
    77 days ago
    Change Detected
    Summary
    The page adds a visible 'Show glossary' option and updates labels to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' with a new revision indicator 'Revision: v3.4.0'; it also removes the lowercase variants 'met QC Criteria' and 'No FEAR Act data' as well as the older 'Revision: v3.3.4'.
    Difference
    0.2%
    Check dated 2026-01-28T21:46:31.000Z thumbnail image

Stay in the know with updates to Cabozantinib in Pancreatic Neuroendocrine & Carcinoid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib in Pancreatic Neuroendocrine & Carcinoid Tumors Clinical Trial page.